Glucosylceramide Synthase Inhibitor class drugs
3 results
Cerdelga (eliglustat)
(eliglustat)Genzyme Corporation
Usage: CERDELGA is indicated for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are CYP2D6 extensive, intermediate, or poor metabolizers. It is not recommended for ultra-rapid metabolizers or patients with indeterminate CYP2D6 genotypes due to potential inadequate therapeutic effect.
Miglustat (miglustat)
(miglustat)CoTherix, Inc.
Usage: Miglustat is indicated as monotherapy for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not an option due to allergy, hypersensitivity, or poor venous access.
Zavesca (miglustat)
(miglustat)Actelion Pharmaceuticals US, Inc.
Usage: ZAVESCA is indicated as a standalone treatment for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not viable due to factors like allergy, hypersensitivity, or inadequate venous access.